期刊文献+

鲍曼不动杆菌耐药机制及治疗策略研究进展 被引量:20

Recent advances in resistance mechanisms of Acinetobacter baumannii and treatment strategies
下载PDF
导出
摘要 鲍曼不动杆菌具有强大的获得耐药性和克隆传播的能力,对多种抗生素的耐药机制非常复杂。多重耐药、泛耐药鲍曼不动杆菌呈世界性流行,已成为我国院内感染最重要的病原菌之一,为院内感染治疗提出了新的挑战。因此,明确鲍曼不动杆菌的耐药机制并制定有效的治疗策略有重要的意义。本文对鲍曼不动杆菌耐药机制和治疗策略的最新进展进行综述。 Acinetobacter baumannii has the potent abilities of acquiring drug resistance and clonal propagation, and the mechanisms of resistance to multiple antibiotics are very complex. Multidrugresistant and pandrugresistant Acinetobacter baumannii are prevalent worldwide and in China Acinetobacter baumannii has become one of the most important pathogens that cause nosocomial infections, which has posed new challenges for the treatment of nosocomial infections. So it is of great importance to recognize the resistance mechanisms and formulate effective treatment strategies. This article gives an overview of the recent advances in the resistance mechanisms of Acinetobacter baumannii and treatment strategies to combat Acinetobacter baumannii infections.
出处 《传染病信息》 2014年第3期184-188,共5页 Infectious Disease Information
基金 全军医学科技"十二五"科研项目重点课题(BWS11-C073) 国家"十二五"科技重大专项(2013ZX10004203001)
关键词 鲍曼不动杆菌 抗药性 抗菌药 治疗学 Acinetobacter baumannii drug resistance anti-bacterial agents therapeutics
  • 相关文献

参考文献45

  • 1Landelle C,Legrand P,Lesprit P. Protracted outbreak of multidrug-resistant Acinetobacter baumannii after intercontinental transfer of colonized patients[J].Infection Control and Hospital Epidemiology,2013,(02):119-124.
  • 2Mosqueda N,Espinal P,Cosgaya C. Globally expanding carbapen-emase finally appears in Spain:nosocomial outbreak of Acinetoba-cter baumannii producing plasmid-encoded OXA-23 in Barcelona,Spain[J].Antimicrobial Agents and Chemotherapy,2013,(10):5155-5157.
  • 3Peleg AY,Seifert H,Paterson DL. Acinetobacter baumannii:emer-gence of a successful pathogen[J].Clinical Microbiology Reviews,2008,(03):538-582.
  • 4Nicola C,David W. Multidrug-resistant Acinetobacter baumannii:mechanisms of virulence and resistance[J].Intern J Antimicrob Agents,2010,(03):219-226.
  • 5Fournier PE,Vallenet D,Barbe V. Comparative genomics of multidrug resistance in Acinetobacter baumannii[J].PLoS Genetics,2006,(01):e7-11.
  • 6Iacono M,Villa L,Fortini D. Whole genome pyrosequencing of an epidemic multidrug-resistant Acinetobacter baumannii strain belonging to the European clone Ⅱ group[J].Antimicrobial Agents and Chemotherapy,2008,(07):2616-2625.
  • 7Adams MD,Goglin K,Molyneaux N. Comparative genome sequence analysis of multidrug-resistant Acinetobacter baumannii[J].Journal of Bacteriology,2008,(24):8053-8064.
  • 8Post V,Hall RM. AbaR5,a large multiple-antibiotic resistance re-gion found in Acinetobacter baumannii[J].Antimicrobial Agents and Chemotherapy,2009,(06):2667-2671.
  • 9Alsultan AA,Hamouda A,Evans BA. Acinetobacter bauman-nii:emergence of four strains with novel blaOXA-51-like genes in pa-tients with diabetes mellitus[J].Journal of Chemotherapy,2009,(03):290-295.
  • 10Turton JF,Woodford N,Glover J. Identification of Acineto-bacter baumannii by detection of the blaOXA-51-like carbapene mase gene intrinsic to this species[J].Journal of Clinical Microbiology,2006,(08):2974-2976.

二级参考文献52

  • 1汪复.多重耐药铜绿假单胞菌与鲍曼不动杆菌严重感染的防治策略[J].中国感染与化疗杂志,2007,7(3):230-232. 被引量:138
  • 2杜正隆,庞晓军,韦华.治疗多重耐药铜绿假单胞菌感染的临床探究[J].中国药房,2007,18(23):1801-1802. 被引量:21
  • 3Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America[J]. Clin Infect Dis, 2009, 48(1):1-12.
  • 4Fischbach MA, Walsh CT. Antibiotics for emerging pathogens[J]. Science, 2009, 325(5944):1089-1093.
  • 5Bazan JA, Martin SI, Kaye KM. New beta-lactam antibiotics: doripenem, ceftobiprole, ceftaroline, and cefepime[J]. Infect Dis Clin North Am, 2009, 23(4):983-996.
  • 6Jansee-Ortho Inc. Zeftera, ceftobiprole medocaril for injection[EB/ OL]. [2010-11-20]. http://www.janssen-ortho.com/joi/pdf_files/ Zeftera_E.pdf.
  • 7Steed ME, Rybak MJ. Ceftaroline, a new cephalosporin with activity against resistant gram-positive pathogens[J]. Pharmacotherapy, 2010, 30(4):375-389.
  • 8Anderson DL. Doripenem[J]. Drugs Today (Bare), 2006, 42(6):399-404.
  • 9Koga T, Masuda N, Kakuta M, et al. Potent in vitro activity of to-mopenem (CS-023)against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa[J]. Antimicrob Agents Chemother, 2008, 52(8):2849-2854.
  • 10Ross DB. The FDA and the case of Ketek[J]. New Engl J Med, 2007, 356(16):1601-1604.

共引文献12

同被引文献179

  • 1孟彦彬,王文军,吴新辉.柴胡桂枝汤的免疫调节作用的实验研究[J].陕西中医,2008,29(7):917-918. 被引量:22
  • 2侯盼飞,应春妹,汪雅萍,叶杨芹,张灏旻.耐碳青霉烯类抗生素鲍曼不动杆菌产β内酰胺酶研究[J].中国感染与化疗杂志,2010,10(4):285-289. 被引量:25
  • 3周忠清,郑今兰,张劲松,刘荣,石祥恩.开颅术后颅内感染的诊断与治疗[J].中华医院感染学杂志,2005,15(4):402-404. 被引量:47
  • 4许宏涛,张秀珍.医院感染铜绿假单胞菌多重耐药机制的研究[J].中国抗感染化疗杂志,2005,5(3):141-145. 被引量:58
  • 5靳桂明,董玉梅,余爱荣,张瞿璐.开颅手术后颅内感染流行病学调查的荟萃分析[J].中国临床神经外科杂志,2007,12(3):149-151. 被引量:91
  • 6Sogam'd M, Ncrgam'd M, Dethlefsen C, et al. Temporal changes in the incidence and 30-day mortality associated with bacteremia in hospitalized patients from 1992 through 2006: a population-based cohort study[J]. Clin Infect Dis, 2011, 52(1):61-69.
  • 7U.S. Centers for Disease Control and Prevention. Bloodstream infection event (central line-associated bloodstream infection and non-central line-associated bloodstream infection)[EB/OL]. [2015-02-01].http://www.cdc.gov/nhsn/PDFs/pscManual/PSC_CLABScurrent.pdf.
  • 8Richards MJ, Edwards JR, Culver DH, et al. Nosocomial infections in combined medical-surgical intensive care units in the United States [ J ]. Infect Control Hosp Epidemiol, 2000, 21 (8):510-515.
  • 9Bartoletti M, Giannella M, Caraceni P, et al. Epidemiology and outcomes of bloodstream infection in patients with cirrhosis[J]. J Hepatol, 2014, 61(1):51-58.
  • 10Magret M, Lisboa T, Martin-Loeches I, et al. Bacteremia is an in- dependent risk factor for mortality in nosocomial pneumonia: a pro- spective and observational malticenter study[J]. Crit Care, 2011, 15(1):R62.

引证文献20

二级引证文献88

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部